Literature DB >> 31364981

Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis.

Cemal Bes1.   

Abstract

Interstitial lung disease (ILD) is one of the extra-articular involvement forms of rheumatoid arthritis (RA), and it is associated with increased mortality. The presence of genetic susceptibility, smoking, rheumatoid factor positivity, and the presence of anticitrulline peptide antibodies are factors contributing to the development of ILD in patients with RA. Early diagnosis and treatment of ILD contribute to the reduction of morbidity and mortality. We herein evaluated the current literature for the diagnosis and treatment of RA-associated ILD.

Entities:  

Year:  2018        PMID: 31364981      PMCID: PMC6668644          DOI: 10.5152/eurjrheum.2019.19036

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  38 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia.

Authors:  Sarah R Atkins; Carl Turesson; Jeffery L Myers; Henry D Tazelaar; Jay H Ryu; Eric L Matteson; Tim Bongartz
Journal:  Arthritis Rheum       Date:  2006-02

Review 3.  Genetics of fibrosing lung diseases.

Authors:  J C Grutters; R M du Bois
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

4.  Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.

Authors:  Shunsuke Mori; Fumiya Imamura; Chikage Kiyofuji; Mineharu Sugimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

5.  Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT.

Authors:  Fumiko Kinoshita; Hidefumi Hamano; Hiromi Harada; Toshibumi Kinoshita; Tadashi Igishi; Hiroshi Hagino; Toshihide Ogawa
Journal:  Respir Med       Date:  2004-11       Impact factor: 3.415

6.  The differing patterns of subclinical pulmonary involvement in connective tissue diseases as shown by application of factor analysis.

Authors:  F Salaffi; P Manganelli; M Carotti; S Baldelli
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

Review 7.  Pulmonary manifestations of rheumatoid arthritis.

Authors:  Umair A Gauhar; Angelo L Gaffo; Graciela S Alarcón
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

8.  Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis.

Authors:  J Biederer; A Schnabel; C Muhle; W L Gross; M Heller; M Reuter
Journal:  Eur Radiol       Date:  2003-10-14       Impact factor: 5.315

9.  Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis.

Authors:  T Takeuchi; Y Tatsuki; Y Nogami; N Ishiguro; Y Tanaka; H Yamanaka; N Kamatani; M Harigai; J Ryu; K Inoue; H Kondo; S Inokuma; T Ochi; T Koike
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

10.  Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

View more
  6 in total

1.  Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.

Authors:  Mona Nili; David Singer; Maya Hanna
Journal:  BMC Pulm Med       Date:  2022-04-23       Impact factor: 3.320

Review 2.  Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential.

Authors:  Marco Sebastiani; Paola Faverio; Andreina Manfredi; Giulia Cassone; Caterina Vacchi; Anna Stainer; Maria Rosa Pozzi; Carlo Salvarani; Alberto Pesci; Fabrizio Luppi
Journal:  Biomedicines       Date:  2020-12-26

3.  Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients.

Authors:  Dilek Tezcan; Abdullah Sivrikaya; Dilek Ergün; Halil Özer; Duygu Eryavuz Onmaz; Muslu Kazım Körez; Turan Akdağ; Semral Gülcemal; Muhammet Limon; Sema Yılmaz
Journal:  Clin Rheumatol       Date:  2021-06-14       Impact factor: 2.980

Review 4.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

5.  Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study.

Authors:  Giulia Cassone; Andreina Manfredi; Fabiola Atzeni; Vincenzo Venerito; Caterina Vacchi; Valentina Picerno; Federica Furini; Gian Luca Erre; Paola Tomietto; Anna Laura Fedele; Giovanni Della Casa; Valeria Nucera; Chiara Giannitti; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

6.  Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-κB pathway.

Authors:  Yijiang Huang; Kaizhe Chen; Huachen Yu; Daosen Chen; Lianfu Deng; Yu Zhang; Xinghe Xue; Xiaoyun Pan
Journal:  Cell Cycle       Date:  2020-03-01       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.